Patents by Inventor Gary Peter Bembridge

Gary Peter Bembridge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)
    Publication number: 20210017270
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: July 9, 2020
    Publication date: January 21, 2021
    Inventors: Gary Peter BEMBRIDGE, Chun-wa CHUNG, Susannah Karen FORD, Ian KIRBY, Ruth MCADAM, Maria FEENEY
  • Antigen binding proteins to oncostatin M (OSM)
    Patent number: 10808029
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: October 20, 2020
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
  • ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)
    Publication number: 20170152312
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: February 9, 2017
    Publication date: June 1, 2017
    Inventors: Gary Peter BEMBRIDGE, Chun-wa Chung, Susannah Karen FORD, Ian KIRBY, Ruth MCADAM, Maria FEENEY
  • Antigen binding proteins to Oncostatin M (OSM)
    Patent number: 9605063
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: March 28, 2017
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
  • ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)
    Publication number: 20150064201
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 5, 2015
    Inventors: GARY PETER BEMBRIDGE, CHUN-WA CHUNG, SUSANNAH KAREN FORD, IAN KIRBY, RUTH MCADAM, MARIA FEENEY
  • Antigen binding proteins to oncostatin M (OSM)
    Patent number: 8916695
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: December 23, 2014
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-Wa Chung, Maria Feeney, Susannah Karen Ford, Ian Kirby, Ruth McAdam
  • ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)
    Publication number: 20130251724
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: November 21, 2011
    Publication date: September 26, 2013
    Applicant: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-Wa Chung, Maria Feeney, Susannah Karen Ford, Ian Kirby, Ruth McAdam
  • IL-23 ANTIBODIES
    Publication number: 20110206686
    Abstract: The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).
    Type: Application
    Filed: October 3, 2008
    Publication date: August 25, 2011
    Inventors: Gary Peter Bembridge, Jane Elizabeth Clarkson, Jonathan Henry Ellis, Paul Andrew Hamblin, George Kopsidas, Alan Peter Lewis, Ruth Mcadam
  • IMMUNOGLOBULINS
    Publication number: 20090123479
    Abstract: The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA).
    Type: Application
    Filed: October 3, 2008
    Publication date: May 14, 2009
    Inventors: Gary Peter Bembridge, Jane Elizabeth Clarkson, Jonathan Henry Ellis, Paul Andrew Hamblin, George Kopsidas, Alan Peter Lewis, Ruth McAdam
  • Vaccination
    Publication number: 20080145375
    Abstract: The present invention relates to improved nucleic acid vaccines, adjuvant systems, and processes for the preparation of such vaccines and adjuvant systems. In particular, the nucleic acid vaccines and adjuvant systems of the present invention comprise a combination of a nucleotide sequence encoding GM-CSF, or derivatives thereof, and toll-like receptor (TLR) agonists, or derivatives thereof.
    Type: Application
    Filed: September 13, 2004
    Publication date: June 19, 2008
    Applicant: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Jennifer L Craigen